MGIC Investment walked out of its last report with one of its cleaner scorecards in years: new insurance written at its highest level since 2022, a sixth straight dividend increase, lower expense guidance and book value up 10% from a year earlier. The market has responded by marking the stock down almost 10% while the S&P 500 gained 4%. That gap, nearly 14 percentage points of underperformance, frames the third-quarter report due after the close on November 4. Either investors are pricing in credit trouble that has not yet shown up in the numbers, or a business improving at the margin has been left behind.
The Street is not asking for much. Consensus calls for earnings of $0.80 a share on revenue of $301.1 million, down 3.6% and 1.1% from a year ago. That is a modest step back from the $0.87 posted last quarter, though revenue would actually tick up from $295.4 million. The softer earnings estimate likely reflects caution about loss provisions more than any doubt about the premium base. Management did not issue formal earnings guidance, so the clearest yardstick is its pledge to keep full-year operating expenses toward the low end of a $190 million to $200 million range. Second-quarter opex of $46 million kept that goal well in reach, and a similar run rate would confirm the discipline is real rather than seasonal.
Credit is the swing factor. The delinquency rate rose 16 basis points from a year earlier to 2.37% last quarter, extending a normalization that has unfolded slowly for three years. Management still assumes a 7.5% claim rate on new delinquencies, and cures came in better than expected, producing $43 million of favorable reserve development. That release flattered last quarter's earnings, and it is the least predictable line in the model. If delinquencies tick up seasonally but cures keep beating assumptions, the orderly normalization story holds and the $0.80 bar looks conservative. A sharper rise in new notices, or a quarter with little or no reserve release, would challenge it and could explain why the stock has struggled.
On the top line, the question is whether volume can offset erosion. New insurance written climbed to $18 billion in the spring buying season, but third-quarter volume will show whether that strength carries forward or was mostly seasonal. Meanwhile, persistency has slipped from 85% to 83% over the past year, meaning more policies are rolling off, and in-force premium yield keeps edging lower, around 38 basis points. With insurance in force growing just 2.6% a year, further persistency slippage would make even flat revenue harder to achieve. Management has been clear it will return capital rather than chase growth, so buybacks and the newly raised $0.17 dividend matter as much as volume.
The capital story also hinges on reinsurance. MGIC's program now cuts required assets under PMIERs by $3.1 billion, roughly 52%, up from 43% a year earlier, helped by a new $168 million excess-of-loss deal covering 2027 business. Continued gains here free up capital and support further returns, which is a key reason book value keeps compounding.
Sentiment has cooled noticeably, moving from essentially neutral before the last report to moderately bearish now. The stock, at $28.72, sits above its 200-day average of $27.73 and in the middle of its post-earnings range between $25.68 and $31.89, so the chart is not signaling a decisive verdict. That leaves the fundamentals to settle the argument. The central issue is whether credit normalization remains slow and well reserved. If it does, the gap between steadily rising book value and a falling share price becomes hard to justify.